A pre-IND meeting is a formal consultation with the FDA that a sponsor requests before submitting an Investigational New Drug (IND) application — the point at which a drug or biologic developer can put open questions about nonclinical data, chemistry/manufacturing/controls (CMC), and the proposed first-in-human protocol directly to the review division that will eventually receive the IND. It is optional, not a regulatory requirement, but it is the standard mechanism sponsors use to reduce the risk of a clinical hold or a rejected IND once the real submission is filed. This guide covers what a pre-IND meeting is for, how it is classified and requested under FDA’s formal meeting framework, what the briefing package needs to contain, and how the timeline works end to end.
What a Pre-IND Meeting Is For
Before a sponsor can legally administer an investigational drug or biologic to human subjects in the United States, it must have an active IND on file with the FDA under 21 CFR Part 312. Filing an IND is a substantial undertaking: it requires nonclinical pharmacology and toxicology data sufficient to justify testing in humans, CMC information describing how the product is manufactured and controlled, and a proposed clinical protocol. A pre-IND meeting exists to surface problems with any of these components before the sponsor commits to a full submission, when a design or data gap is still cheap to fix.
Typical questions sponsors bring to a pre-IND meeting include:
- Whether the nonclinical toxicology package is adequate to support the proposed starting dose and duration of the first-in-human trial
- Whether the overall nonclinical program (pharmacology, pharmacokinetics, toxicology) is sufficient to proceed, or whether additional studies are needed first
- Whether the CMC data package is adequate for the phase of development being proposed
- Whether the proposed Phase 1 protocol design, dose-escalation scheme, and safety stopping rules are acceptable
- Whether the product may qualify for a special regulatory pathway or designation that affects how the IND should be structured
A pre-IND meeting does not obligate FDA to any particular future decision on the IND itself, and FDA’s written responses are advisory based on the information provided at the time — but a well-prepared pre-IND meeting is the single most effective tool a sponsor has for avoiding a 30-day clinical hold after the IND is actually filed.
Is a Pre-IND Meeting Required?
No. Nothing in 21 CFR Part 312 requires a sponsor to hold a pre-IND meeting before submitting an IND. In practice, most sponsors request one anyway for a novel product, a new mechanism of action, a first-in-class modality, or any program where the nonclinical or CMC package involves genuine judgment calls about adequacy. Sponsors with a well-precedented product class, or those relying heavily on a cross-reference to an existing Master File or a previously reviewed program, sometimes skip it. Academic and investigator-initiated IND sponsors — a physician who both initiates and conducts the investigation, a common structure in institutional research — are frequent pre-IND meeting requesters specifically because they often have less in-house regulatory experience than a commercial sponsor and more to gain from an early check-in with the review division.
Pre-IND Meetings Are Type B Meetings
FDA classifies its formal meetings with sponsors into four types — A, B, C, and D — under its meeting-management guidance for PDUFA products, with the procedural mechanics for all of them grounded in 21 CFR 312.82 (Early Consultation) for IND-stage meetings specifically. A pre-IND meeting is a Type B meeting, the same category as an End-of-Phase 2 meeting or a pre-NDA/BLA meeting — a milestone consultation at a defined development stage, as distinct from a Type A meeting (reserved for stalled programs or safety issues needing urgent resolution) or a Type C meeting (any other product-development question outside the defined milestones). Each sponsor is generally entitled to one Type B meeting per development phase per product, which is why sponsors are encouraged to consolidate every open nonclinical, CMC, and clinical-design question into a single, well-organized pre-IND request rather than raising them piecemeal.
How to Request a Pre-IND Meeting
The request is a short written submission to the review division expected to receive the eventual IND (the division is determined by therapeutic area/product type), typically submitted to FDA’s electronic submission gateway. A complete meeting request states the proposed meeting type (Type B), the product and its proposed indication, a brief development history, the specific list of questions the sponsor wants addressed, and a short list of proposed attendees and their roles.
Per FDA’s formal-meeting timelines for PDUFA products, the review division notifies the sponsor whether the meeting is granted within 21 calendar days of receiving the request, and a granted Type B meeting is generally scheduled to occur within 60 calendar days of FDA’s receipt of the request. FDA may also offer to respond to the sponsor’s questions in writing only (a “written response only” meeting), in lieu of holding a live meeting, when that is judged sufficient to resolve the questions raised.
The Pre-IND Briefing Package
If the meeting is granted, the sponsor must submit a briefing package (sometimes called the briefing document) that FDA guidance specifies should reach the review division no later than 30 calendar days before the scheduled meeting date — in practice this gives a sponsor roughly four to six weeks after the meeting is granted to prepare it. The briefing package is the substantive document the review team actually works from; the original meeting request is intentionally brief by comparison. A well-organized briefing package typically includes:
- A concise overview of the product, its proposed mechanism, and the development rationale
- A summary of nonclinical pharmacology, pharmacokinetics, and toxicology data supporting the proposed first-in-human study
- A summary of the CMC information available at the pre-IND stage
- The proposed clinical protocol synopsis, including dose-escalation design, starting dose rationale, and safety monitoring/stopping rules
- The specific numbered questions the sponsor wants FDA to address, organized to match the meeting agenda — not restated from the meeting request, but expanded with the supporting data needed for FDA to actually answer each one
FDA reviewers read the briefing package in advance and frequently provide written preliminary responses to the sponsor’s questions a few days before the meeting itself, which is why the meeting conversation is often narrower and more targeted than the original question list — some questions get resolved by the written preliminary response alone, leaving the live meeting time for genuine points of disagreement or nuance.
What Happens During and After the Meeting
Type B meetings are typically scheduled for about an hour and are conducted by teleconference or videoconference far more often than in person. FDA’s meeting attendees usually include the assigned regulatory project manager and representatives from the relevant clinical, nonclinical/pharmacology-toxicology, and CMC review disciplines. The sponsor should expect FDA to walk through its preliminary written responses to the submitted questions and to use the live discussion for follow-up and clarification rather than for reopening every question from scratch.
FDA issues official minutes of the meeting to the sponsor, generally within about 30 calendar days of the meeting date. These minutes — not the sponsor’s own notes — are the official record of what was agreed, and become the reference document the sponsor cites when the IND is eventually submitted (for example, “per FDA guidance provided at the [date] pre-IND meeting”). Keeping the minutes, the briefing package, and the meeting request together as part of the regulatory file is standard practice, since reviewers of the eventual IND may reference back to commitments made during this meeting.
Pre-IND Meetings in Context: The Investigator-Initiated IND
For academic sponsors filing an Investigator IND, the pre-IND meeting carries extra weight because the investigator is typically both the sponsor and the treating physician, without a commercial sponsor’s dedicated regulatory affairs function behind the submission. Research administration offices and clinical trials offices supporting an investigator-initiated IND commonly treat the pre-IND meeting as a required internal milestone even though FDA itself does not require it — it is the point at which a novel-drug, novel-device, or unusual-protocol program gets an early read from the actual review division before the institution commits significant time and cost to a full IND package. See CASRAI’s guide to clinical trial phases for how the pre-IND stage fits into the broader trajectory from first-in-human study through later-phase development, and the IRB/REC approval process guide for the parallel ethics-review track that runs alongside, but independently of, FDA’s IND pathway — a pre-IND meeting addresses FDA’s regulatory questions; it does not substitute for IRB review of the same protocol.
Frequently Asked Questions
Does a pre-IND meeting cost anything?
FDA does not charge a fee for a pre-IND meeting itself. PDUFA user fees apply to marketing applications (NDAs/BLAs) and certain other later-stage submissions, not to IND-stage formal meetings.
Can a pre-IND meeting be a written-response-only meeting instead of a live discussion?
Yes. FDA may propose, or a sponsor may request, that the review division respond to the submitted questions in writing only, without a live meeting, when the questions are narrow enough that a written response is sufficient.
What is the difference between a pre-IND meeting and the IND submission itself?
The pre-IND meeting is an optional advisory consultation that happens before any IND exists. The IND application (via Form FDA 1571 and its supporting content) is the actual regulatory filing under 21 CFR Part 312 that must be active before human dosing can begin; it triggers FDA’s 30-calendar-day safety review clock, during which FDA can place the study on clinical hold.
How far in advance should a sponsor start preparing for a pre-IND meeting?
Given the 21-day grant decision, up to a 60-day scheduling window, and a briefing package due 30 days before the meeting, sponsors typically plan for roughly four to five months from submitting the meeting request to receiving final FDA minutes. Nonclinical and CMC data packages should be far enough along by the time of the request that the sponsor’s questions are answerable, not open-ended.
Who at FDA attends a pre-IND meeting?
Attendance varies by product and division, but typically includes a regulatory project manager plus reviewers from the clinical, pharmacology/toxicology, and CMC disciplines relevant to the proposed program — the same review team likely to handle the eventual IND.
